Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HELP

Helus Pharma Inc

6.09

Jul 08 • 09:52AM ET +0.06 (0.95%)

Healthcare Biotechnology Canada Small NASD

Peers: GLSI RZLT IMRX ACIU ARTV AVXL NGEN PALI PRLD TARA

| Held by: PSIL QQQS

Scroll to Statements

Index	-
Market Cap	377.27M
Enterprise Value	220.01M
Income	-148.00M
Sales	0.00M
Book/sh	4.49
Cash/sh	2.54
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	100
IPO	Sep 13, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.36
P/C	2.40
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.52
Current Ratio	9.52
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-4.43
EPS next Y	-2.29
EPS next Q	-0.86
EPS this Y	33.96%
EPS next Y	18.23%
EPS next 5Y	27.20%
EPS past 3/5Y	16.70% 14.41%
Sales past 3/5Y	- -
EPS Y/Y TTM	-9.48%
Sales Y/Y TTM	-
EPS Q/Q	8.35%
Sales Q/Q	-
Earnings	Jun 30 BMO
EPS/Sales Surpr.	-12.74% -

Insider Own	21.45%
Insider Trans	0.00%
Inst Own	29.79%
Inst Trans	-6.72%
ROA	-68.70%
ROE	-74.63%
ROIC	-63.85%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	15.68%
SMA50	22.13%
SMA200	1.85%
Trades

Shs Outstand	51.63M
Shs Float	48.69M
Short Float	6.39%
Short Ratio	2.60
Short Interest	3.11M
52W High	9.12 -33.26%
52W Low	3.76 61.89%
Volatility	6.54% 8.26%
ATR (14)	0.40
RSI (14)	62.05
Beta	0.58
Rel Volume	1.82
Avg Volume	1.20M
Volume	225,726

Perf Week	-7.91%
Perf Month	46.67%
Perf Quarter	15.94%
Perf Half Y	-21.25%
Perf YTD	-25.59%
Perf Year	-20.22%
Perf 3Y	-65.40%
Perf 5Y	-92.78%
Perf 10Y	-
Recom	1.00
Target Price	31.00
Prev Close	6.03
Price	6.09
Change	0.95%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-26	Initiated	TD Cowen	Buy	$8
Feb-02-26	Initiated	Jefferies	Buy	$22
Mar-13-25	Initiated	Guggenheim	Buy	$35
Nov-19-21	Downgrade	Maxim Group	Buy → Hold

Jul-06-26 03:53PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -5.61%
Jun-29-26 07:40AM	Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results (GlobeNewswire) +6.17%
Jun-26-26 09:30AM	A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year (PR Newswire) +7.64%
Jun-25-26 09:27AM	Helus Pharma Announces Closing of US$50 Million Underwritten Offering (GlobeNewswire) +18.27%
Jun-24-26 06:01AM	Helus Pharma Announces US$50 Million Underwritten Offering (GlobeNewswire)
06:00AM	Loading…
06:00AM	Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress (GlobeNewswire)
Jun-22-26 08:00AM	BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing (TMX Newsfile)
Jun-11-26 07:30AM	Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference (GlobeNewswire)
Jun-01-26 07:30AM	Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-13-26 08:00AM	BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director (TMX Newsfile)
May-04-26 11:11AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Apr-30-26 07:17PM	CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health (GlobeNewswire) +8.15%
07:30AM	Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference (GlobeNewswire)
Apr-28-26 07:30AM	Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health (GlobeNewswire)
Apr-23-26 07:30AM	Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan (GlobeNewswire)
08:15AM	Loading…
Apr-20-26 08:15AM	Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions (GlobeNewswire)
08:00AM	Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer (GlobeNewswire)
Apr-16-26 07:30AM	Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs (GlobeNewswire)
Mar-12-26 07:30AM	Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer (GlobeNewswire)
Mar-09-26 10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire) +5.14%
Mar-08-26 11:17AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks) -6.91%
Mar-05-26 10:38AM	Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints (Benzinga) -33.88%
09:30AM	Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion (PR Newswire)
07:30AM	Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder (GlobeNewswire)
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire) -5.28%
Feb-26-26 12:07PM	Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders (PR Newswire)
Feb-24-26 09:35AM	Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity (PR Newswire) +9.51%
07:45AM	Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee (GlobeNewswire)
Feb-20-26 11:14AM	Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise (MarketBeat)
09:29PM	Loading…
Feb-18-26 09:29PM	Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers (Insider Monkey) +5.03%
Feb-17-26 07:30AM	Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder (GlobeNewswire) +11.00%
Feb-16-26 02:58PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-13-26 07:31AM	HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-10-26 08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
07:30AM	Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution (GlobeNewswire)
Jan-05-26 07:30AM	HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq (Business Wire) -6.64%
Jan-04-26 04:51PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-20-25 08:02PM	Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges (GuruFocus.com)
Oct-22-25 07:00AM	BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor (NewMediaWire)
Sep-03-25 09:00AM	Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint (TipRanks)
Sep-02-25 03:52AM	Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy (Insider Monkey) -16.58%
Aug-18-25 06:07PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-13-25 05:30PM	Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results (Business Wire) -5.66%
Aug-07-25 07:30AM	Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder (Business Wire)
Aug-06-25 07:30AM	Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Jul-20-25 07:00PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-18-25 09:55AM	Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? (Zacks)
Jul-17-25 07:30AM	Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder (Business Wire) +12.50%
Jul-16-25 09:46AM	3 High-Risk, High-Reward Stocks With Explosive Upside (MarketBeat)
Jul-01-25 11:19AM	REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures (Business Wire) +7.27%
Jun-30-25 10:03PM	Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
09:27PM	Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures (Business Wire)
Jun-25-25 04:08AM	Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development (Insider Monkey) +5.36%
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
Jun-18-25 08:30AM	Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 (Newsfile)
Jun-13-25 07:45AM	Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics (Business Wire)
Jun-12-25 07:30AM	Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference (Business Wire)
Jun-11-25 07:30AM	Cybin to Participate in the 2025 Psychedelic Science Conference (Business Wire)
Jun-03-25 07:30AM	Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder (Business Wire)
May-22-25 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 (Business Wire)
May-20-25 07:30AM	Cybin Applauds FDA Commissioner Dr. Martin Makarys Call to Accelerate and Prioritize Research on Psychedelic Therapeutics (Business Wire) -6.53%
May-15-25 07:30AM	Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder (Business Wire)
May-14-25 07:30AM	Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase (Business Wire)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks) +6.33%
May-08-25 07:30AM	Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder (Business Wire) +6.76%
May-01-25 07:30AM	Cybin to Participate at the 28th Annual Milken Institute Global Conference (Business Wire)
Apr-27-25 03:31PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Apr-25-25 11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
Apr-23-25 07:30AM	Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 (Business Wire)
Apr-21-25 08:00AM	Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs (Business Wire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-04-25 09:35AM	Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-17-25 09:55AM	Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet (Zacks)
Feb-10-25 09:48PM	Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Jan-30-25 09:55AM	Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade (Zacks)
Jan-15-25 12:07PM	Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder (Business Wire)
Jan-13-25 07:30AM	Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 (Business Wire)
Jan-09-25 05:00PM	Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (Business Wire)
Dec-10-24 07:30AM	Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results (Business Wire)
Dec-04-24 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 (Business Wire)
Nov-18-24 07:00AM	Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder (Business Wire) -8.62%
Nov-14-24 07:30AM	Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 (Business Wire)
Nov-13-24 07:30AM	Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results (Business Wire) -10.26%
Oct-31-24 07:30AM	Cybin to Participate at the 2024 Milken Institute Future of Health Summit (Business Wire)
Oct-24-24 07:30AM	Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program (Business Wire)
Oct-03-24 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 (Business Wire)
Oct-01-24 07:30AM	Cybin Expands Clinical Team to Support CYB003 Phase 3 Program (Business Wire)
Sep-24-24 07:30AM	Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Business Wire)
Sep-19-24 05:38PM	Cybin Provides Corporate Update on Upcoming Clinical Milestones (Business Wire) +10.42% +7.24%
07:26AM	Cybin Announces Completion of Previously Announced Share Consolidation (Business Wire)
Sep-04-24 07:55AM	Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-27-24 07:01PM	Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation (Business Wire)
Aug-13-24 07:30AM	Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder (Business Wire)
Aug-08-24 07:36AM	Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Aug-07-24 07:30AM	Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Co-FounderMr. Eric So L.L.B.

Co-FounderMr. Paul Glavine

Chief Financial OfficerMr. Greg Cavers

Chief Legal Officer & Corporate SecretaryMr. Gabriel Fahel

Chief Business OfficerMr. George Tziras

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HELP

Helus Pharma Inc

Upgrade your Finviz experience